
Title and author of burned, still-rolled scroll decoded after nearly 2,000 years
Sign up for CNN's Wonder Theory science newsletter. Explore the universe with news on fascinating discoveries, scientific advancements and more.
CNN —
Researchers working to decipher the contents of a burned, still-rolled scroll have uncovered both the author and the title of the text nearly 2,000 years after it was buried in the Mount Vesuvius eruption.
The scroll — named PHerc. 172 — is one of hundreds from the ancient Roman town of Herculaneum, which was buried under volcanic debris when Mount Vesuvius erupted in 79 AD, according to the Vesuvius Challenge, an initiative focused on decoding the texts of the Herculaneum scrolls without needing to unroll them.
Preserved under mud and ash in a villa believed to have been once owned by the father-in-law of Julius Caesar, the scrolls were discovered by an Italian farmer in the 18th century.
Burned so badly they were carbonized, they are extremely fragile. Over the years, scholars have tried a range of methods to unroll them, including using weights, chemicals, gases and pulverization, though this often led to the scrolls being damaged or destroyed.
The Vesuvius Challenge was launched in 2023 to encourage researchers from around the world to try and decipher the scrolls by virtually unwrapping and decoding them.
Now, Marcel Roth and Micha Nowak, graduate students from Germany's University of Würzburg, have uncovered the title and author of PHerc. 172. Vesuvius Challenge researcher Sean Johnson made the same discovery around the same time, and both findings were independently reviewed by the competition's papyrological team, according to a Tuesday press release from Oxford University's Bodleian Libraries, where the scroll is housed.
The text deciphered identifies the scroll as 'On Vices' by the Greek philosopher Philodemus, according to the Vesuvius Challenge. It is a part of Philodemus' ethical treatise known in full as 'On Vices and Their Opposite Virtues and In Whom They Are and About What,' and could even be the first book in the series, though this is not yet clear.
Oxford University's Bodleian Libraries suggests that the book number could 'plausibly' be read as an alpha, which would indicate that the scroll is book one in the series, but it could also be other numbers, such as a delta, which would mean it is book four.
Scholars have generally thought that the first book of 'On Vices' was a text called 'On Flattery,' but the content of PHerc. 172 does not correspond with this.
Philodemus, according to the Bodleian Libraries, was an Epicurean philosopher whose teachings 'emphasise the pursuit of pleasure as central to a good life.' The majority of the scrolls found preserved in the Herculaneum villa were his works, Bodleian Libraries said.
Michael McOsker, a researcher in papyrology at University College London, who is also a member of the Vesuvius Challenge papyrology team, called the new discovery a 'very exciting development.'
'Other books from the On Vices and their Opposite Virtues are known from the papyri that were physically unrolled — best known are On Property Management (book 9, presumably the opposite virtue to greed) and On Arrogance (book 10, presumably the opposite vice to having a correct evaluation of yourself), but there are others too,' McOsker said.
'This will be a great opportunity to learn more about Philodemus' ethical views and to get a better view of the On Vices as a whole, especially if it turns out to be the first book,' McOsker said.
This find, the first time a scroll's title has been read, is the latest from the Vesuvius Challenge.
In October 2023, the first full word from one of the unopened ancient papyri was decoded with the help of computer technology and advanced artificial intelligence. The word was 'πορφυρας' or 'porphyras,' which is Greek for purple.
And in February, researchers investigating columns of text from PHerc. 172 identified the word 'διατροπή,' meaning 'disgust,' which appears twice within a few columns of text, the Bodleian Libraries said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Fox News
a day ago
- Fox News
Dead Sea Scrolls could be even older than previously thought, according to new study
Print Close By Andrea Margolis Published June 05, 2025 The Dead Sea Scrolls may be even older than researchers thought, according to a new study driven by an artificial intelligence (AI) model. A group of researchers from the Netherlands, Italy and Denmark recently published their findings in the journal PLOS One on June 4. The researchers said they developed an AI-based date-prediction model named Enoch, a nod to the biblical patriarch of the same name. ANCIENT CHRISTIAN FIGURINES DISCOVERED IN 1,500-YEAR-OLD DESERT GRAVES Enoch "was trained as a machine learning-based date-prediction model applying Bayesian ridge regression on established handwriting-style descriptors," according to the study. In order to date the scrolls, the model analyzed each one's handwriting style. Researchers also integrated radiocarbon dating methods — and found that most of the scrolls were at least a generation older than previously thought. Previous estimates placed the scrolls between 150 and 50 B.C., but the model found that many of the scrolls date to around 200 B.C. "There are no compelling paleographic or historical reasons that preclude these older dates as reliable time markers." "Enoch's style-based predictions are often older than traditionally assumed paleographic estimates, leading to a new chronology of the scrolls and the re-dating of ancient Jewish key texts that contribute to current debates on Jewish and Christian origins," the paper states. LITTLE GIRL DISCOVERS 3,800-YEAR-OLD AMULET WITH TIES TO BIBLICAL PEOPLE DURING FAMILY TRIP The researchers also indicate that the new dates are "realistic." "There are no compelling paleographic or historical reasons that preclude these older dates as reliable time markers," the authors said. For more Lifestyle articles, visit The scrolls, found in desert caves near the Dead Sea in the 1940s and 1950s, date between the third century B.C. to the first century A.D. They offer a wealth of knowledge about ancient Judaism, with many religious texts during the Second Temple period that were previously unknown. CLICK HERE TO SIGN UP FOR OUR LIFESTYLE NEWSLETTER Since their discovery, the scrolls have attracted a great amount of interest from both scholars and the public at large. In 2021, Israeli researchers uncovered dozens of new Dead Sea Scroll fragments. CLICK HERE TO GET THE FOX NEWS APP In April, the Ronald Reagan Presidential Library showcased a special collection of eight ancient Jewish manuscripts as part of its exhibition on the Dead Sea Scrolls. Print Close URL


Medscape
2 days ago
- Medscape
Targeted Therapy Wins Big for BRAF-Mutated Metastatic CRC
The latest results from the BREAKWATER trial have confirmed encorafenib plus cetuximab with chemotherapy as the new first-line standard of care for BRAF V600E-mutant metastatic colorectal cancer (CRC), according to research presented at the American Society of Clinical Oncology (ASCO) 2025 annual meeting. At the interim analysis, encorafenib plus cetuximab with mFOLFOX6 chemotherapy doubled median overall survival compared with the current standard of care — investigators' choice of chemotherapy with or without bevacizumab. In addition, at a median follow-up of 16.8 months, the new treatment regimen led to a significant improvement in median progression-free survival of almost 6 months. This survival finding is 'unprecedented' and 'practice changing' for these patients who historically have a poor prognosis, said lead investigator and presenter Elena Élez, MD, PhD, a gastrointestinal medical oncologist at the Vall d'Hebron University Hospital in Barcelona, Italy. The study was published in The New England Journal of Medicine to coincide with Élez's presentation. BRAF mutations, which occur in up to 12% of patients with metastatic CRC, are associated with poor outcomes. In December 2024, the US Food and Drug Administration (FDA) granted accelerated approval for the BRAF inhibitor encorafenib alongside cetuximab and mFOLFOX6 for patients with metastatic CRC and a BRAF V600E mutation. This approval was based on earlier results from BREAKWATER that showed a 21% higher objective response rate and a longer duration of response with this regimen. The accelerated approval means that this regimen has already been making its way into the clinic, but 'we were all waiting for this [latest] data,' Pamela Kunz, MD, chief of Gastrointestinal Medical Oncology at Yale University in New Haven, Connecticut, told Medscape Medical News . The doubling of overall survival 'is a big deal,' she said. In the trial, patients were randomly assigned to receive either first-line encorafenib plus cetuximab with mFOLFOX6 (n = 236) or to a control group — physician's choice of either mFOLFOX6, FOLFOXIRI, or CAPOX chemotherapy (n = 243). Most patients in the control arm also received the tumor angiogenesis inhibitor bevacizumab. The broad options in the control arm speak to how heterogeneous treatment has been for BRAF V600E-mutant metastatic CRC, said study discussant Andrea Sartore-Bianchi, MD, a medical oncologist at the University of Milan, Milan, Italy. Patients in the trial had received no prior systemic therapy for metastatic disease. Investigators excluded patients with high levels of microsatellite instability because they are candidates for immunotherapy. At a median follow-up of 16.8 months, median progression-free survival was 12.8 months for the encorafenib group compared with 7.1 months for the control group (hazard ratio [HR], 0.53; P < .0001). At a median follow-up of 22 months, overall survival was 30 months in the encorafenib group compared with 15 months in the control group (HR, 0.49; P < .0001). The benefits of the combination were held up in high-risk subgroups, including in patients with liver metastases and those with metastases in three or more organs. With the use of more agents and a longer duration of treatment due to improved efficacy, there was an expected increase in toxicity with the new regimen. The rate of treatment-related grade 3/4 adverse events was 76.3% with encorafenib vs 58.5% with the control regimen. Patients receiving encorafenib also had higher rates of anemia, arthralgia, rash, and pyrexia, but there was no substantial increase in treatment discontinuation. BREAKWATER also included an encorafenib plus cetuximab arm without chemotherapy, but enrollment was stopped early at 158 patients due to possible futility. Still, these patients had as good or numerically better outcomes than the control group, which means the drug combination alone is a valid option for those unable to tolerate chemotherapy, said Élez. 'The results are striking,' said Sartore-Bianchi in his discussion. 'Now that we have the big picture' from BREAKWATER, the combination should be considered the first-line standard of care. Mark A. Lewis, MD, a gastrointestinal medical oncologist at Intermountain Healthcare in Murray, Utah, explained that what usually happens in metastatic CRC is that people are treated with chemotherapy for a bit before oncologists notice the tumor is behaving more aggressively than expected and order a BRAF test. This delay is now 'completely unacceptable,' he told Medscape Medical News . The takeaway from BREAKWATER is that testing must come sooner. To help with BRAF testing, the FDA approved the Qiagen therascreen BRAF V600E RGQ polymerase chain reaction kit. 'As soon as you know patients are BRAF -mutated, you need to play your entire hand' because it will double survival,' said Lewis. 'This absolutely validates a biomarker-informed approach to colon cancer,' similar to what we have in breast cancer. BREAKWATER was funded primarily by Pfizer, maker of encorafenib, with support from Eli Lilly and Merck, who jointly market cetuximab. Élez reported numerous ties to the companies, including research grants, travel funding, honoraria, and/or consultant work. Lewis, Kunz, and Sartore-Bianchi had no relationships with the firms.


Washington Post
3 days ago
- Washington Post
Our languages have more in common than you might think
In ancient India, the most powerful god was known as 'sky father,' or in the Sanskrit language Dyaus pita. Sound it out. Can you see where this is going? In Greece, his equivalent was Zeus pater; in Rome, Jupiter. English speakers have always been used to tracing the etymologies of their words back to the classical languages of Europe, but the suggestion, in the late 18th century, that there were also clear and consistent features in common with languages spoken much farther to the east was an astonishing and exhilarating one.